Benzinga··Vandana SinghNovartis Acquires Next-Gen Breast Cancer Drug in $3B SNV4818 Deal
Novartis acquires SNV4818, a next-gen PI3Kα inhibitor, from Synnovation for $2B upfront plus $1B milestones to treat PIK3CA-mutated breast cancer.
NVSacquisitionclinical trials